Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Launch innovative vitamin sublingual sprays
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Subscribe To Our Newsletter & Stay Updated
